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Abstract
Many patients with asthma have poorly controlled
symptoms, and particularly for those with severe
disease, there is a clear need for improved treatments.
Two recent therapies licensed for use in asthma are
omalizumab, a humanized monoclonal antibody that
binds circulating IgE antibody, and bronchial
thermoplasty, which involves the delivery of radio
frequency energy to the airways to reduce airway
smooth muscle mass. In addition, there are new
therapies under development for asthma that have
good potential to reach the clinic in the next five
years. These include biological agents targeting pro-
inflammatory cytokines such as interleukin-5 and
interleukin-13, inhaled ultra long-acting b2-agonists
and once daily inhaled corticosteroids. In addition,
drugs that block components of the arachidonic acid
pathway that targets neutrophilic asthma and CRTH2
receptor antagonists that inhibit the proinflammatory
actions of prostaglandin D2 may become available.
We review the recent progress made in developing
viable therapies for severe asthma and briefly discuss
the idea that development of novel therapies for
asthma is likely to increasingly involve the assessment
of genotypic and/or phenotypic factors.
Introduction
Asthma is a chronic inflammatory disease of the airways
that affects over 300 million individuals worldwide [1].
The majority of adults with asthma have mild or moder-
ate disease that can be controlled by inhaled corticoster-
oids either alone or in combination with inhaled long-
acting ß2 agonist bronchodilators [1-3]. Questionnaire
surveys however indicate that a considerable proportion
of these patients [4], as well as most with severe asthma
[5], or who are cigarette smokers [6,7] have poorly con-
trolled asthma. Systematic evaluation can help identify
patients with severe asthma from those with difficult-to-
treat asthma due to poor adherence, untreated co-mor-
bidities, dysfunctional breathing or psychological pro-
blems [8,9]. For patients with severe asthma, which
accounts for 5% to 10% of cases [10], there is a need for
improved therapies [10-12]. This mini-review focuses on
biological agents, new inhaled long-acting bronchodila-
tors and corticosteroids, arachidonic acid pathway
blockers, bronchial thermoplasty plus a range of other
anti-inflammatory agents that have been recently
licensed or are at an advanced stage of development for
patients with severe asthma (Figure 1). In addition, we
briefly discuss the idea that the development of novel
therapies for asthma is likely increasingly to involve the
assessment of genotypic and/or phenotypic factors.
Biological agents
The first and as yet only biological agent licensed for the
treatment of asthma is omalizumab, a humanized mono-
clonal antibody that binds circulating IgE antibody, pre-
venting it from binding to its specific high-affinity
receptor on mast cells and basophils [13]. In patients
with allergic asthma, omalizumab treatment improves
symptoms and reduces exacerbations [14,15]. Clinical
trials are also underway to assess the efficacy of omali-
zumab in non-allergic asthma and in combination with
specific allergen immunotherapy, with the aim of redu-
cing systemic allergic reactions [16]. The adverse effect
profile of omalizumab is generally good [17] although
preliminary data from a five-year safety study has raised
concerns about a trend for increased cardiovascular
events and further confirmation is awaited [18,19].
A number of biological agents have been developed to
target cytokines thought to play an important role in
asthma pathogenesis [20,21], including monoclonal anti-
body blockers of TNF-a, IL-5, IL-4 and IL-13. Unfortu-
nately despite some promise shown in early small
clinical studies with the soluble TNF-a receptor blocker,
etanercept, in severe asthma [22,23], larger studies with
golimumab [24] and etanercept [25] have not confirmed
a consistent effect. Overall, when combined with con-
cerns over increased risk of severe infections and malig-
nancies with treatment [24] it is unlikely that TNF-a
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ment of asthma.
Two recent exploratory studies have examined anti-
IL5 monoclonal antibody (mepolizumab) treatment in
patients with severe asthma [26,27]. In 61 patients with
refractory eosinophilic asthma and a history of recurrent
severe exacerbations mepolizumab treatment reduced
severe exacerbations [27] (Figure 2) and in 20 patients
with severe oral corticosteroid dependent asthma an
oral corticosteroid sparing effect was observed [26].
Phase 3 trials are now underway. The relevance of this
approach to clinical practice has been debated [28] as
possibly only a small proportion of patients with persis-
tent sputum eosinophilia are also concordant with
inhaled or oral corticosteroid treatment [29].
A number of clinical trials employing monoclonal
antibodies targeting IL-4 and/or IL-13 in asthma are
underway [30,31]. Both cytokines exert their actions
through the IL-4Ra/IL-13Ra1 receptor complex.
Blocking IL-13 binding to the IL-4 receptor a with
IMA-638 reduces allergen-induced bronchoconstric-
tion [32]. Pitrakinra, a recombinant protein that binds
to IL-4Ra, reduces allergen-induced late responses
with few adverse events [33] and is undergoing devel-
opment as an inhaled medication. A clearer picture of
t h er o l eo fI L - 4a n dI L - 1 3b l o c k e r si nt h et r e a t m e n to f
severe asthma is likely to emerge over the next few
years.
Daclizumab is a humanized monoclonal antibody that
binds specifically to the CD25 subunit of the high-affi-
nity IL-2R, and inhibits IL-2 binding and T-cell activa-
tion. A pilot study of daclizumab in patients with
moderate to severe asthma reported minor improve-
ments in lung function and asthma control [34].
Figure 1 Potential targets for selected novel therapies for treatment resistant asthma. The figure summarizes targets for a selection of
therapies that are recently licensed or under clinical development for patients with severe treatment resistant asthma. Abbreviations: CRTH2,
chemoattractant receptor-homologous molecule expressed on Th2 cells; FLAP, lipoxygenase-activating protein; IL-, interleukin-; PPAR, proliferator-
activated receptor; PDE, phosphodiesterase; PGD2, prostaglandin D2.
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respiratory viruses due to impaired Th1 immunity [35]
and immunological augmentation with inhaled inter-
feron b to aid anti-viral responses at the time of the
exacerbation is currently under assessment.
New inhaled long-acting bronchodilators and
corticosteroids
In addition to the development of novel therapies, refine-
ments in the pharmacological properties of drugs cur-
rently used to treat asthma, such as long-acting b2-
agonists and inhaled corticosteroids is a major focus of the
pharmaceutical industry. Inhaled ultra long-acting b2-ago-
nists (ultra-LABAs) such as indacaterol, currently licensed
for COPD, have a longer half-life than current LABAs and
are suitable for once daily administration [36,37]. Fixed
combinations of ultra-LABAs with once daily inhaled cor-
ticosteroids as well as once daily inhaled corticosteroids
alone are at an advanced stage of development for the
treatment of asthma. Once daily administration should be
more convenient for patients and may improve adherence.
New inhaled long-acting antimuscarinic agents (LAMAs)
agents such as aclidinium, may also have a role in the
treatment of severe asthma associated with persistent air-
flow obstruction [38,39]. Non-steroidal selective glucocor-
ticoid receptor modulators are in development with the
aim of improving the therapeutic ratio of corticosteroids
by dissociating transactivation, which is associated with
the adverse effects of corticosteroids, from the beneficial
effect of transrepression [40-43].
Arachidonic acid pathway blockers
Pro-inflammatory cysteinyl leukotrienes (LTs) are
synthesized from arachidonic acid by 5-lipoxygenase
(LO) and 5-lipoxygenase-activating protein (FLAP) in
inflammatory airway cells. In addition to inhibiting the
production of the cysteinyl LTs, 5-LO and FLAP inhibi-
tors such as GSK-2190915 [44] prevent the formation of
LTB4, which may be of value in neutrophilic asthma.
Prostaglandin (PG)D2 is released from mast cells and
other inflammatory cells and elevated bronchoalveolar
lavage concentrations of PGD2 are reported in severe
asthma [45]. PGD2 activates the CRTH2 receptor (che-
moattractant receptor-homologous molecule expressed
on Th2 cells) resulting in inflammation and a number of
antagonists of the CRTH2 receptor are being assessed
for the treatment of asthma [46].
Bronchial thermoplasty
Bronchial thermoplasty involves the delivery of radio
f r e q u e n c ye n e r g yt ot h ea i r w a y sb yf l e x i b l eb r o n c h o -
scopy with the aim of reducing airway smooth muscle
mass and responsiveness in asthma [47-50]. Initial clini-
cal studies including the Asthma Intervention Research
(AIR)1 trial found that bronchial thermoplasty reduces
exacerbations and improves morning peak expiratory
flow and symptoms in patients with severe asthma
[51-53]. The AIR2 trial reported the results of a com-
parison with sham bronchial thermoplasty in 288 adult
subjects with severe asthma [54]. Bronchial thermoplasty
resulted in improvements from baseline in Asthma
Quality of Life Questionnaire (AQLQ) scores compared
with sham (bronchial thermoplasty, 1.35 versus sham,
1.16), with 79% of bronchial thermoplasty and 64% of
sham subjects achieving changes in AQLQ of 0.5 or
greater (Figure 3). It is of interest that the sham bron-
chial thermoplasty was associated with a large increase
in AQLQ scores. In the post-treatment period, the bron-
chial thermoplasty group also experienced fewer severe
exacerbations and emergency department visits. How-
ever bronchial thermoplasty was associated with a short-
term increase in asthma-related morbidity. Long-term
five-year safety data for patients recruited to the AIR1
trial [52] reported absence of clinical complications and
maintenance of stable lung function [55]. In 2010 bron-
chial thermoplasty was approved by the United States
Food & Drug Administration (FDA) for the treatment of
severe persistent asthma. Future research needs to iden-
tify factors that best predict a therapeutic response to
bronchial thermoplasty.
Other anti-inflammatory drugs
A number of novel drugs under development may prove
to have a role in the management of asthma. Phospho-
diesterase (PDE)4 inhibitors have immunomodulatory
Figure 2 Cumulative number of severe exacerbations in each
study group over the course of 50 weeks treatment with
mepolizumab or placebo. Mean number of exacerbations per
subject over the course of the 50-week treatment period was 2.0 in
the mepolizumab group, compared with 3.4 in the placebo group
(relative risk, 0.57; 95% confidence interval, 0.32 to 0.92; P = 0.02).
Reproduced from Haldar et al with permission [27]. Copyright (c)
Massachusetts Medical Society.
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relevant to the treatment of severe asthma [56]. High
doses of phosphodiesterase (PDE)4 inhibitors may be
necessary to treat severe asthma, and gastro-intestinal
side effects may limit their use [56-58], although inhaled
PDE4 inhibitors may improve their therapeutic index
[59,60]. Inhibition of protein kinases such as p38 mito-
gen-activated protein kinase (MAPK) and other tyrosine
kinases involved in cellular signalling of pro-inflamma-
tory cytokines may have a role in the treatment of
severe asthma [61-63]. For example, a phase 3 study
e v a l u a t i n gat y r o s i n ek i n a s ei n h i b i t o ro ft h ec - K I T
receptor masitinib commenced recently.
Several drugs licensed for treating other conditions
may also have a role in the management of asthma. In a
randomized controlled trial of 58 patients with severe
asthma with fungal sensitiza t i o n( S A F S )[ 6 4 ]t h eo r a l
anti-fungal drug itraconazole administered for 32 weeks
resulted in improvement in AQLQ scores [65]. However
the risk of adrenal suppression with long-term treatment
with itraconazole in patients also receiving inhaled corti-
costeroids has led to some caution in adopting this
management strategy [66,67]. Peroxisome proliferator-
activated receptor-g (PPARg) agonists exert anti-inflam-
matory effects on eosinophilic and neutrophilic infiltra-
tion of the lungs of experimental animals [68]. A proof
of concept study using the PPARg agonist rosiglitazone,
demonstrated bronchodilator effects in mild to moder-
ate smokers with asthma [69] and further clinical trials
of oral PPARg agonists are underway in severe asthma.
Statins have pleiotropic anti-inflammatory effects poten-
tially relevant to the treatment of asthma [70-76]. Short-
term treatment of patients with mild to moderate
asthma with statins does not improve symptoms or lung
function [77-80], although AQLQ scores improve in
asthmatic smokers [80]. The small peptide endothelin
causes bronchoconstriction and may contribute to air-
way remodelling in asthma [81,82]. A 12-month clinical
trial of the endothelin receptor antagonist sitaxsentan is
underway in patients with severe asthma.
Factors influencing the response to novel therapies
Genotypic and phenotypic factors can influence the
response to drug treatment for asthma [23,26,27,83]. For
example, adrenergic b2-receptor polymorphisms, parti-
cularly variants at position 16 (Gly16Arg) and 27
Figure 3 Total Asthma Quality of Life Questionnaire (AQLQ) score over 12 months after treatment with bronchial thermoplasty (BT)
(diamonds) or sham control (squares) in the per protocol population. *Posterior probability of superiority = 97.9%. Reprinted with
permission of the American Thoracic Society. Copyright
© American Thoracic Society [54] Official Journal of the American Thoracic Society.
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odilator response to short and long-acting b2-receptor
agonists and naturally occurring mutations in the pro-
moter of 5-lipoxygenase gene (ALOX5) may influence
the clinical response to drugs modifying the 5-lipoxy-
genase pathway [84-86]. Several inflammatory pheno-
types, which have been identified mainly on the basis of
induced sputum cell profiles, influence the response to
drug treatment [87,88]. For example, sputum eosinophi-
lia predicts corticosteroid responsiveness [89-93] and
the response to the anti-IL-5 blocker mepolizumab in
severe asthma [26,27]. Non-eosinophilic asthma, a term
used to describe an absence of raised numbers of
inflammatory cells (also known as paucigranulocytic
inflammation) or neutrophilic inflammation, responds
less well to inhaled corticosteroids [91-93]. Macrolides
may be effective in neutrophilic asthma [94]. Th2-high
asthma, as defined by gene expression analyses of airway
cells, predicts an improvement in lung function with
inhaled corticosteroids in patients with mild to moder-
ate disease, whereas patients with Th2-low asthma
respond poorly to inhaled corticosteroids [95]. The
development of novel therapies for severe asthma in the
future is likely to involve genotypic and/or phenotypic
assessment to identify patients who will gain the most
from a specific intervention.
Conclusions and future directions
Omalizumab, a humanized monoclonal antibody that
binds circulating IgE antibody, and bronchial thermo-
plasty, where radio frequency energy is delivered to the
airways to reduce airway smooth muscle mass are valu-
able additional therapies for the management of severe
asthma. There is a need to identify new therapies that
are effective and safe and target sub-phenotypes of
asthma. Of therapies currently under development, bio-
logical agents directed at blocking pro-inflammatory
cytokines such as interleukin-5 and interleukin-13, ultra
long-acting b2-agonists and once daily inhaled corticos-
teroids as well as drugs blocking components of the ara-
chidonic acid pathway such as FLAP inhibitors and
CRTH2 receptor antagonists have the greatest potential
to reach the clinic. In the future, both genotypic and
phenotypic factors are likely to guide the choice of
intervention in each individual with severe asthma.
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